GB2284154A - Anti-aging compositions for cosmetic use - Google Patents
Anti-aging compositions for cosmetic use Download PDFInfo
- Publication number
- GB2284154A GB2284154A GB9420224A GB9420224A GB2284154A GB 2284154 A GB2284154 A GB 2284154A GB 9420224 A GB9420224 A GB 9420224A GB 9420224 A GB9420224 A GB 9420224A GB 2284154 A GB2284154 A GB 2284154A
- Authority
- GB
- United Kingdom
- Prior art keywords
- agent
- cosmetic composition
- skin
- cosmetic
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 239000002537 cosmetic Substances 0.000 title claims abstract description 23
- 230000003712 anti-aging effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 35
- 102000008186 Collagen Human genes 0.000 claims abstract description 15
- 108010035532 Collagen Proteins 0.000 claims abstract description 15
- 229920001436 collagen Polymers 0.000 claims abstract description 15
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims abstract description 14
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims abstract description 14
- 101001010513 Homo sapiens Leukocyte elastase inhibitor Proteins 0.000 claims abstract description 14
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 12
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 12
- 229960002424 collagenase Drugs 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 7
- 230000009759 skin aging Effects 0.000 claims description 7
- 230000003796 beauty Effects 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- -1 fatty acid ester Chemical class 0.000 abstract description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 4
- XUARCIYIVXVTAE-ZAPOICBTSA-N uvaol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C XUARCIYIVXVTAE-ZAPOICBTSA-N 0.000 abstract description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 abstract description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 abstract description 2
- 239000005642 Oleic acid Substances 0.000 abstract description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract description 2
- 229960005070 ascorbic acid Drugs 0.000 abstract description 2
- 235000010323 ascorbic acid Nutrition 0.000 abstract description 2
- 239000011668 ascorbic acid Substances 0.000 abstract description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 abstract description 2
- 229960002591 hydroxyproline Drugs 0.000 abstract description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract description 2
- 239000001648 tannin Substances 0.000 abstract description 2
- 235000018553 tannin Nutrition 0.000 abstract description 2
- 229920001864 tannin Polymers 0.000 abstract description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 abstract description 2
- SYFNOXYZEIYOSE-UHFFFAOYSA-N uvaol Natural products CC1CCC2(O)CCC3(C)C(=CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C SYFNOXYZEIYOSE-UHFFFAOYSA-N 0.000 abstract description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 abstract 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 abstract 1
- 102000029816 Collagenase Human genes 0.000 abstract 1
- 108060005980 Collagenase Proteins 0.000 abstract 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 229910021645 metal ion Inorganic materials 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012190 activator Substances 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 235000019766 L-Lysine Nutrition 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940071160 cocoate Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000002194 fatty esters Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000037393 skin firmness Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- MLTOQTGCMBIFFL-MOPGFXCFSA-N (2s,4r)-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@H]1CN[C@H](C(O)=O)C1 MLTOQTGCMBIFFL-MOPGFXCFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical class OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Compositions comprise a combination of an anti-elastase agent, an anti-collagenase agent and an agent that stimulates collagen III synthesis in an cosmetic excipient. Anti elastase agents may be tannin, oleic acid, uvaol or alpha -2 macroglobulin. The anti collagenases may be EDTA, L-cysteine, metal ions or mercaptans. Collagen III synthesis stimulators may be a fatty acid ester of ascorbic acid or hydroxyproline etc.
Description
COSMETIC COMPOSITION AND BEAUTY TREATMENT
METHOD COUTERACTING SKIN AGEING
The present invention relates to a cosmetic composition comprising an effective amount of a combination of three types of substances displaying different activities.
The present invention also relates to a beauty treatment method counteracting skin aging.
In order to alleviate the phenomenon of skin aging, cosmetology has developed various cosmetic compositions.
These compositions can contain nutrients for the cells (amino acids, sugars, vitamins, etc), constituent components of the skin (collagen, elastin, essential fatty acids, factors, NNF, etc) and agents affording protection against the external environment (free-radical scavengers, film-forming agents, anti-WA screening agents, etc).
Since the activity of these different cosmetic compositions is relatively short-lived and only slightly effective, it hence proved useful to develop cosmetic compositions displaying lasting and effective activity.
The authors of the present invention discovered, surprisingly, that the combination of an effective amount of three types of known substances had a synergistic activity for counteracting skin aging, in comparison with the activity of the substances taken separately.
Thus, the present invention relates to a cosmetic composition, characterized in that it comprises an effective amount of a combination of an anti-elastase agent, an anti-collagenase agent and an agent that stimulates collagen III synthesis, in a suitable cosmetic excipient.
As an agent that stimulates collagen synthesis, it is possible to use the products described in Patent
Application EP-0,537,092 and in Patent Application FR 93/05,050. These products comprise, as an agent that stimulates collagen III synthesis, fatty esters of ascorbic acid, and in particular its palmitate., the palmitate of collagen hydrolysate and the fatty esters of hydroxyamino acids such as hydroxyproline, and more especially its palmitate.
These agents are contained in vesicular carriers which can be liposomes obtained, for example, according to the process described in FR-A-2,649,335 or nanospheres.
Vesicles comprising phospholipids and hydroxyproline palmitate in combination with cholesterol are especially preferred.
The single-membrane phospholipid structure of these "carriers is rhombohedral. They thus afford a surface/volume ratio greater than that of spherical carriers.
This composition is described as having a stimulatory activity that triggers. a non-dose-dependent response by fibroblasts, arousing in them their capacity to synthesize collagen III.
This stimulatory activity is due to the rhombohedral structure and to the mixture of the three substances in an effective amount. Thus, in carriers of phospholipid type, the phospholipids (lecithin) represent 70 to 95% by weight on a dry basis, cholesterol represents 1 to 15% by weight on a dry basis and the amino acid/alcohol dipalmitate 1 to 15% by weight on a dry basis of the composition.
This composition counteracts the phenomenon of skin aging.
As regards the preparation of the composition that stimulates collagen III synthesis, it is necessary to work in a sterile medium with equipment which is also sterilized. The active principles, in well-defined proportions, are mixed according to a precise order.
The anti-collagenase agent can be a chelating agent such as EDTA, L-cysteine, metals such as Peck, CuZ and Zn++ and mercaptans, it being possible for the anticollagenases to be of natural origin, plant origin and serum origin (ss1-anti-collagenase, a2-macroglobulin).
Reference may be made in this connection to "Handbook of
Enzyme Inhibitors", 2nd Edition, A and B by Helmward Zollner, pp. 131 to 135.
The anti-elastase agent may be chosen from antielastases of plant origin such as tannin, oleic acid, the triterpene uvaol and cucurbita maxima; anti-elastases of fungal origin such as cephalosporin; anti-elastases of serum origin such as a2-macroglobulin; and anti-elastases of natural origin, and the like (propionylamino acid derivatives, thiazolidinecarboxylic acid derivatives).
Reference may be made in this connection to "Handbook of Ellzyme Inhibitors", 2nd Edition, A and B by Helmward
Zollner, pp. 195 to 199).
Preferably, the combination of the anti-elastase and anti-collagenase agents and the agent that stimulates collagen III synthesis represents 0.3 to 10% by weight of the composition, and the different agents are present in the proportion of 0.1 to 5% by weight of the composition.
The appropriate cosmetic excipients are, of course, chosen according to whether the compositions are in the form of a cream, a fluid emulsion or a gel.
The activity of the cosmetic compositions of the present invention was tested in comparison with that of compositions comprising the three agents separately.
The tests consist in examining the pattern of micro-depressions (PmD) of the skin by computer-aided vision (CAV) and measuring the depth of the wrinkle, as well as measuring skin firmness.
The objective of the evaluation of the structural components of the micro-contours of the skin is to evaluate in man the effect of a cosmetic or body hygiene product on the structural components of the microcontours of the skin, using a quantification by CAV.
The tests are carried out on healthy volunteer subjects, informed beforehand of the nature of the experiment and who have given their informed consent.
Precision imPression of the skin:
- XANTOPRENs VL (BAYER), low viscosity material based on silicone crosslinking by condensation.
- OPTOSILs - XANTOPRENQ ACTIVATOR (BAYER), liquid activator.
- Farbkonzentrat BLAU RL, blue dye.
Image analyser:
This comprises:
- An IVC 800 BC video camera (SONY) equipped with an MD MACRO 50 mm 1:3.5 objective; 8 = 55 mm (MINOLTA) and connected to a monitor (SONY);
- An IBM PC compatible microcomputer;
- An image analysis techniques training software package, MICROMORPH (Centre de Morphologie Mathmatique de l'Ecole des Nines de Paris (Mathematical Morphology
Centre of Paris School of Miners3).
Equipment: - Binocular magnifier (NIKON).
The method is as follows:
The exploration are a varies in accordance with the indication for which the product is tested. Ana comical landmarks are chosen in order to define the area carefully. In the present case, the skin of the face is the region which will be tested.
The impression mixture is prepared at the time of use: 2.5 grams of XANTOPRENS VL and 45 milligrams of
Farbkonzentrat BIAU RL are mixed with 3 drops of OPTOSIL - XANTOPREN ACTIVATOR for 30 seconds.
Impression-taking is performed before treatment on unwashed skin which has not received any product for at least 8 hours.
Subjects are settled comfortably, and the plane of inclination of the head is determined. Using a spatula, the impression mixture is rapidly applied in a uniform layer to the exploration area. The surface covered is approximately 25 to 30 cm2. The setting time in order to permit polymerization is approximately 2 minutes. Detachment of the impression takes place from the upper edge, in the direction of the hairs and the down.
Impression-taking on treated skin is done as an immediate effect, either 15 minutes after application of the product and/or after a frequency and a time of application which are defined by the instigator of the experiment.
Impressions are examined using a binocular magnifier at a magnification of 15 and/or 20. A carefully identified area is stored in the computer memory and quantification of the different structural components of the micro-contours of the skin, pattern of surface micro-depressions (PmD) and polygons, is done by computer-aided vision.
The results of the effect of the products tested on the changes in the structural components of the microcontours of the skin are expressed by:
- The differences between the integrals of the structural components of the micro-contours of the skin, pattern of surface micro-depressions (PmD) and polygons, before and after treatment.
The changes are calculated according to the formula:
Integral after treatment - Integral before
treatment
x 100
Integral before treatment
- Clinical appraisal of the structural components of the micro-contours of the skin observed with the binocular magnifier before and after treatment.
The measurement of skin firmness has as its principle suction of the epidermis with a probe under a constant partial vacuum which is adjustable from 0 to 500 mbar depending on the areas to be studied.
The movement of the epidermis in the probe is measured by two optical lenses.
The rise of the epidermis corresponds to the extensibility, its fall to the tonicity.
The ratio of the tonicitv extensibility measurements is calculated by computer and evaluates the firmness, between 0 and 1.
The equipment comprises:
- 1 SEM 474 firmness gauge
- 1 AMSTRAD 1640 SD computer
- 1 PANASONIC KX P1124 printer
The protocol consists in performing, after adjusting the partial vacuum in mbar and the time of rise and release of the epidermis in the probe, a series of three measurements on a particular area before and after treatment, under identical conditions.
The two tests described above gave results which show that the combination of an effective amount of the anti-elastase and anti-collagenase agents and the agent that stimulates collagen III synthesis has a synergistic effect for counteracting skin aging, compared to the effect obtained under the same conditions with the three agents tested separately.
The subject of the present invention is also a beauty treatment method counteracting skin aging, characterized in that an effective amount of a cosmetic composition according to the present invention is applied to the skin.
In the different formulations which follow, the expression "firmness complex" means "combination of the three types of substances according to the invention", that is to say from 0.1 to 5% of each of the agents, namely an anti-elastase agent, an anti-collagenase agent and an agent that stimulates collagen III synthesis.
Examples of typical cosmetic compositions are the following:
EXAMPLE 1
Care Cream
Demineralized water qs Ce/C1O Triglyceride 1 to 10 %
Glyceryl trilaurate 1 to 5 %
Silicone 1 to 8 %
Glucate SSe 1 to 15 %
Stearic acid 1 to 10 %
Cetyl alcohol 1 to 8 %
Polyacrylic acid 1 to 5 %
Triethanolamine 0.1 to 1 %
Preservatives 0.3 to 1 %
Firmness complex 0.3 to 10 %
EXAMPLE 2
Fluid Emulsion
Demineralized water gs
Propylene glycol 1 to 3 %
Glycerol 1 to 8 %
PCA 0.05 to 1 %
L-Lysine 0.2 to 1 %
Na, EDTA 0.01 to 0.1 %
Carbopol 9419 0.1 to 2 %
Stearoxydimethicone 0.5 to 3 %
Ethylhexyl cocoate 5 to 8 %
Mineral oil 1 to 15 %
Arlacel 60e 1 to 8 %
Brij 58e 0.1 to 1 %
Preservatives 0.3 to 1 %
Firmness complex 0.3 to 10 %
EXAMPLE 3
Gel
Demineralized water gep Glycerol 5 to 20 %
Na, EDTA 0.01 to 0.5 % Sepigel 305 Preservatives 0.3 to 1 %
Firmness complex 0.3 to 10 % Example of prenaration of the fluid emulsion:
A gel is prepared by introducing Carbopol 941 powder (0.1 to 2% by weight) with vigorous agitation into cold water, which is vortexed.
Separately, an aqueous phase is prepared by mixing the components propylene glycol (1 to 3% by weight), glycerol (1 to 8%), PCA (0.05 to 1%), L-lysine (0.2 to 1%), Na4 EDTA (0.01 to 0.1%) and preservatives (0.3 to 1%). The abovementioned mixture is then heated to 70-750C with agitation and the gel prepared above is thereafter introduced into the aqueous phase.
The fatty phase is prepared by heating the collective constituents stearoxydimethicone (0.5 to 3%), ethylhexyl cocoate (5 to 8%), mineral oil (1 to 15%), Arlacel 60 (1 to 8%) and Brij 58 (0.1 to 1%) to 75-800C. The fatty phase is then drawn into the aqueous phase with the gel. A vacuum is applied. The mixture is allowed to cool to 350C in order to introduce the "firmness complex" (0.3 to 10% by weight). The mixture is agitated and allowed to cool under vacuum. At 250C, tie agitation is stopped and the preparation is checked.
Claims (8)
1. Cosmetic composition, cdmprising an effective amount of a combination of an anti-elastase agent, an anti-collagenase agent and an agent that stimulates collagen III synthesis, in a suitable cosmetic excipient.
2. Cosmetic composition according to Claim 1, in which the combination of an antielastase agent, a-1 anti-collagenase agent and an agent that stimulates collagen III synthesis represents 0.3 to 10% by weight of the composition.
3. Cosmetic composition according to Claims 1 and 2, in which the anti-elastase agent is present in the proportion of 0.1 to 5% by weight of the composition.
4. Cosmetic composition according to Claims 1 and 2, in which the anti-collagenase agent is present in the proportion of 0.1 to 5% by weight of the composition.
5. Cosmetic composition according to Claims 1 and 2, in which the agent that stimulates collagen III synthesis is present in the proportion of 0.1 to 5% by weight of the composition.
6. Cosmetic composition according to any one of the preceding claims, in the form of a cream, a fluid emulsion ot a gel.
7. Beauty treatment method counteracting skin aging, in which an effective amount of a cosmetic composition according to Claims 1 to 6 is applied to the skin.
8. A cosmetic composition substantially as hereinbefore described with reference to Examples 1 to 3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9312040A FR2710839B1 (en) | 1993-10-08 | 1993-10-08 | Cosmetic composition and aesthetic treatment method opposing aging of the skin. |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9420224D0 GB9420224D0 (en) | 1994-11-23 |
GB2284154A true GB2284154A (en) | 1995-05-31 |
Family
ID=9451687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9420224A Withdrawn GB2284154A (en) | 1993-10-08 | 1994-10-07 | Anti-aging compositions for cosmetic use |
Country Status (4)
Country | Link |
---|---|
ES (1) | ES2072230B1 (en) |
FR (1) | FR2710839B1 (en) |
GB (1) | GB2284154A (en) |
IT (1) | IT1267465B1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1005333A1 (en) * | 1997-02-25 | 2000-06-07 | The University Of Michigan | Methods and compositions for preventing and treating chronological aging in human skin |
EP1163900A1 (en) * | 1998-11-05 | 2001-12-19 | Protease Sciences, Incorporated | Cosmetic compositions containing human type serine protease inhibitors |
WO2002096291A1 (en) * | 2001-05-30 | 2002-12-05 | Unilever Plc | Cosmetic product with a device for evaluating its efficacy and method of using the latter |
AU2002304622B2 (en) * | 2001-05-30 | 2004-12-16 | Unilever Plc | Wrinkle indicator tape strip and method of using the same |
US8895034B2 (en) | 2011-11-02 | 2014-11-25 | Mark K Bennett | Collagen production compound |
US10155733B2 (en) | 2015-04-28 | 2018-12-18 | Conopco, Inc. | N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same |
US10307355B2 (en) | 2015-04-28 | 2019-06-04 | Conopco, Inc. | N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2746316B1 (en) * | 1996-03-19 | 1998-06-12 | Guerlain | NEW COSMETOLOGICAL OR DERMATOLOGICAL COMPOSITIONS |
JP5725864B2 (en) * | 2010-08-06 | 2015-05-27 | 株式会社 資生堂 | Elastase inhibitor |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2683720A1 (en) * | 1991-11-15 | 1993-05-21 | Jouvance Daniel | Composition for cosmetic use containing particles of a gelled substance |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2546164B1 (en) * | 1983-05-16 | 1987-07-17 | Centre Nat Rech Scient | NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ELASTASE INHIBITORS |
DE3788300D1 (en) * | 1986-05-14 | 1994-01-13 | Floersheim Georg L | Pharmaceutical preparation for preventing free radical damage to living cells or for increasing the effectiveness of organic sulfur compounds and method for increasing the lifespan of isolated organs. |
FR2611140B1 (en) * | 1987-02-20 | 1991-02-22 | Lamaison Jean Louis | PROCESS FOR OBTAINING TANNIC PRINCIPLES OF PLANT ORIGIN, COSMETOLOGICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING THE PURIFIED TANNIC PRINCIPLE OBTAINED ACCORDING TO THE PROCESS |
FR2666226B1 (en) * | 1990-08-30 | 1994-10-28 | Jean Noel Thorel | PROTECTIVE SKIN COMPOSITION. |
FR2670672B1 (en) * | 1990-12-21 | 1995-02-03 | Sanofi Sa | COSMETIC COMPOSITIONS BASED ON PLANT EXTRACTS. |
EP0537092A1 (en) * | 1991-10-08 | 1993-04-14 | Patrinove Societe Civile | Infracellular vesicular vectors and their application in cosmetic and medical compositions and culture media |
-
1993
- 1993-10-08 FR FR9312040A patent/FR2710839B1/en not_active Expired - Fee Related
-
1994
- 1994-10-07 GB GB9420224A patent/GB2284154A/en not_active Withdrawn
- 1994-10-07 ES ES09402180A patent/ES2072230B1/en not_active Expired - Lifetime
- 1994-10-07 IT IT94TO000790A patent/IT1267465B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2683720A1 (en) * | 1991-11-15 | 1993-05-21 | Jouvance Daniel | Composition for cosmetic use containing particles of a gelled substance |
Non-Patent Citations (1)
Title |
---|
WPI Accession No. 93-260440/33 & FR 2683720 A1 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1005333A1 (en) * | 1997-02-25 | 2000-06-07 | The University Of Michigan | Methods and compositions for preventing and treating chronological aging in human skin |
EP1005333A4 (en) * | 1997-02-25 | 2001-03-14 | Univ Michigan | Methods and compositions for preventing and treating chronological aging in human skin |
EP1163900A1 (en) * | 1998-11-05 | 2001-12-19 | Protease Sciences, Incorporated | Cosmetic compositions containing human type serine protease inhibitors |
WO2002096291A1 (en) * | 2001-05-30 | 2002-12-05 | Unilever Plc | Cosmetic product with a device for evaluating its efficacy and method of using the latter |
AU2002304622B2 (en) * | 2001-05-30 | 2004-12-16 | Unilever Plc | Wrinkle indicator tape strip and method of using the same |
AU2002312889B2 (en) * | 2001-05-30 | 2004-12-16 | Unilever Plc | Cosmetic product with a device for evaluating its efficacy and method of using the latter |
US6875444B2 (en) | 2001-05-30 | 2005-04-05 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Wrinkle indicator tape strip |
US6926904B2 (en) | 2001-05-30 | 2005-08-09 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic product with proof device |
US8895034B2 (en) | 2011-11-02 | 2014-11-25 | Mark K Bennett | Collagen production compound |
US10155733B2 (en) | 2015-04-28 | 2018-12-18 | Conopco, Inc. | N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same |
US10307355B2 (en) | 2015-04-28 | 2019-06-04 | Conopco, Inc. | N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same |
Also Published As
Publication number | Publication date |
---|---|
ITTO940790A0 (en) | 1994-10-07 |
FR2710839A1 (en) | 1995-04-14 |
IT1267465B1 (en) | 1997-02-05 |
ITTO940790A1 (en) | 1996-04-07 |
ES2072230A1 (en) | 1995-07-01 |
GB9420224D0 (en) | 1994-11-23 |
FR2710839B1 (en) | 1995-12-08 |
ES2072230B1 (en) | 1996-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0633764B1 (en) | Skin care method and composition | |
RU2120794C1 (en) | Cosmetic composition for protecting, nourishing and/or firming of superficial and more deep integument and method for protecting, nourishing and/or firming the skin | |
EP0633765B1 (en) | Skin care method and composition | |
US3957971A (en) | Moisturizing units and moisturizing compositions containing the same | |
EP0739195B1 (en) | Skin tanning compositions | |
RU2125442C1 (en) | Composition for skin care and method of skin care | |
EP0684040B1 (en) | Skin treatment composition | |
US20020137691A1 (en) | Pharmaceutical compositions and methods for reducing the appearance of cellulite | |
EP0957888A1 (en) | Lip treatment containing live yeast cell derivative | |
CN101677912A (en) | Gel useful for the delivery of cosmetic active ingredients | |
CN110882186A (en) | Composition with effects of controlling oil, shrinking pores and relieving and preparation method thereof | |
JP2013521251A (en) | Beauty composition | |
US20220160607A1 (en) | Anti-aging cosmetic compositions | |
GB2284154A (en) | Anti-aging compositions for cosmetic use | |
CN110279643A (en) | A kind of reparation efficacy and the preparation method and application thereof | |
JP5105962B2 (en) | Cornified envelope formation / maturation promoter | |
JP3687747B2 (en) | Topical skin preparation | |
US11382858B2 (en) | Active ingredient obtained from Nymphaea alba flowers | |
DE69533714T2 (en) | Lactate dehydrogenase inhibitors in cosmetic products | |
KR20120061048A (en) | Use of isoleucine n-hexadecanoyl as a "volumizing" and/or "plumping" agent for human skin | |
US5882661A (en) | Composition and method for topical application to skin, hair and nails | |
JPH11180851A (en) | Skin cosmetic | |
JPH0967229A (en) | Beautifully whitening cosmetic | |
WO2020175703A1 (en) | Aqueous dispersion for cosmetic preparation, cosmetic preparation composition, and method for producing cosmetic preparation | |
JPH09255546A (en) | Skin preparation for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |